Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt N/A
AMRI's Cash-to-Debt is ranked higher than
61% of the 610 Companies
in the Global Biotechnology industry.

( Industry Median: 49.39 vs. AMRI: N/A )
Ranked among companies with meaningful Cash-to-Debt only.
AMRI' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.13  Med: 5.55 Max: N/A
Current: N/A
Equity-to-Asset 0.27
AMRI's Equity-to-Asset is ranked lower than
83% of the 483 Companies
in the Global Biotechnology industry.

( Industry Median: 0.63 vs. AMRI: 0.27 )
Ranked among companies with meaningful Equity-to-Asset only.
AMRI' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.27  Med: 0.8 Max: 0.96
Current: 0.27
0.27
0.96
WACC vs ROIC
14.01%
-0.12%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -3.29
AMRI's Operating Margin % is ranked higher than
64% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -50.65 vs. AMRI: -3.29 )
Ranked among companies with meaningful Operating Margin % only.
AMRI' s Operating Margin % Range Over the Past 10 Years
Min: -36.35  Med: 1.19 Max: 11.32
Current: -3.29
-36.35
11.32
Net Margin % -12.30
AMRI's Net Margin % is ranked higher than
61% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -43.94 vs. AMRI: -12.30 )
Ranked among companies with meaningful Net Margin % only.
AMRI' s Net Margin % Range Over the Past 10 Years
Min: -31.74  Med: -1.54 Max: 8.97
Current: -12.3
-31.74
8.97
ROE % -23.97
AMRI's ROE % is ranked higher than
51% of the 544 Companies
in the Global Biotechnology industry.

( Industry Median: -24.74 vs. AMRI: -23.97 )
Ranked among companies with meaningful ROE % only.
AMRI' s ROE % Range Over the Past 10 Years
Min: -48.86  Med: -1.72 Max: 6.22
Current: -23.97
-48.86
6.22
ROA % -7.65
AMRI's ROA % is ranked higher than
63% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: -21.99 vs. AMRI: -7.65 )
Ranked among companies with meaningful ROA % only.
AMRI' s ROA % Range Over the Past 10 Years
Min: -17.99  Med: -1.15 Max: 5.29
Current: -7.65
-17.99
5.29
ROC (Joel Greenblatt) % -6.43
AMRI's ROC (Joel Greenblatt) % is ranked higher than
69% of the 585 Companies
in the Global Biotechnology industry.

( Industry Median: -218.94 vs. AMRI: -6.43 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
AMRI' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -35.54  Med: 1.43 Max: 13.51
Current: -6.43
-35.54
13.51
3-Year Revenue Growth Rate 24.30
AMRI's 3-Year Revenue Growth Rate is ranked higher than
76% of the 435 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. AMRI: 24.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
AMRI' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -1.6  Med: 8.5 Max: 78
Current: 24.3
-1.6
78
GuruFocus has detected 2 Warning Signs with Albany Molecular Research Inc $AMRI.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» AMRI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

AMRI Guru Trades in Q1 2016

Jim Simons 323,242 sh (+42.84%)
Chuck Royce 1,079,469 sh (+9.46%)
Ken Fisher 203,450 sh (unchged)
Murray Stahl 56,000 sh (unchged)
Paul Tudor Jones Sold Out
» More
Q2 2016

AMRI Guru Trades in Q2 2016

Paul Tudor Jones 12,500 sh (New)
Chuck Royce 1,183,969 sh (+9.68%)
Murray Stahl 56,000 sh (unchged)
Ken Fisher 203,450 sh (unchged)
Jim Simons 117,942 sh (-63.51%)
» More
Q3 2016

AMRI Guru Trades in Q3 2016

Jim Simons 347,242 sh (+194.42%)
Paul Tudor Jones 14,744 sh (+17.95%)
Chuck Royce 1,254,296 sh (+5.94%)
Murray Stahl 56,000 sh (unchged)
Ken Fisher 157,794 sh (-22.44%)
» More
Q4 2016

AMRI Guru Trades in Q4 2016

Jim Simons 357,900 sh (+3.07%)
Chuck Royce 1,290,911 sh (+2.92%)
Murray Stahl 56,000 sh (unchged)
Paul Tudor Jones Sold Out
Ken Fisher 80,589 sh (-48.93%)
» More
» Details

Insider Trades

Latest Guru Trades with AMRI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 541711    SIC: 8731
Compare:OTCPK:PHMMF, NAS:ARDX, NAS:ANIP, NAS:VNDA, OTCPK:GNFTF, NAS:CLLS, NAS:PGNX, NAS:ANIK, OTCPK:IPHYF, OTCPK:SXMDF, NAS:ESPR, NAS:KERX, NAS:VSAR, NAS:ACHN, NAS:IMMU, NAS:AMAG, NAS:ZIOP, NAS:OMER, NAS:INO, NAS:MESO » details
Traded in other countries:AYM.Germany,
Albany Molecular Research Inc is a contract research and manufacturing organization providing customers drug discovery, development and manufacturing services.

Albany Molecular Research Inc is a Delaware corporation incorporated on June 20, 1991. It is a contract research and manufacturing organization providing customers integrated drug discovery, development and manufacturing services. The Company provides services and technologies that support the discovery and development of pharmaceutical products and the manufacturing of Active Pharmaceutical Ingredients (API) and drug product for existing and experimental new drugs, as well as research, development and manufacturing for the agrochemical and other industries. With locations in the United States, Europe, and Asia, it maintains geographic proximity and flexible cost models. The Company has organized its activities into two distinct segments: Large Scale Manufacturing (LSM) and Discovery, Drug Development and Small-Scale Manufacturing (DDS). Its LSM activities include pilot- to commercial-scale production of active pharmaceutical ingredients and intermediates, sterile syringe and vial filling, and high potency and controlled substance manufacturing. Its remaining activities, including drug lead discovery, in vitro biology and DMPK, lead optimization, drug development, and small-scale commercial manufacturing, represent its DDS business segment. Its Drug Discovery Services includes assay development and design, screening, natural product services, custom synthesis and library synthesis, medicinal chemistry, bioanalytical services, among others. Its customers include pharmaceutical companies and biotechnology companies, as well as government research entities and non-profit organizations, which are a growing segment of its customer base. It also sells to a more limited extent, to companies who are in the businesses of agriculture, fine chemicals, contract chemical manufacturing, medical devices, and flavoring and cosmetics. The Company competes with contract research companies, contract drug manufacturing companies, research and academic institutions and with the internal research departments of biotechnology companies. The manufacture, transportation and storage of its products are subject to certain international, Federal, state and local laws and regulations.

Ratios

vs
industry
vs
history
Forward PE Ratio 13.55
AMRI's Forward PE Ratio is ranked higher than
74% of the 76 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. AMRI: 13.55 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 1.89
AMRI's PB Ratio is ranked higher than
73% of the 556 Companies
in the Global Biotechnology industry.

( Industry Median: 3.85 vs. AMRI: 1.89 )
Ranked among companies with meaningful PB Ratio only.
AMRI' s PB Ratio Range Over the Past 10 Years
Min: 0.29  Med: 1.12 Max: 3.09
Current: 1.89
0.29
3.09
PS Ratio 1.02
AMRI's PS Ratio is ranked higher than
93% of the 477 Companies
in the Global Biotechnology industry.

( Industry Median: 9.96 vs. AMRI: 1.02 )
Ranked among companies with meaningful PS Ratio only.
AMRI' s PS Ratio Range Over the Past 10 Years
Min: 0.32  Med: 1.4 Max: 3.06
Current: 1.02
0.32
3.06
Price-to-Operating-Cash-Flow 77.11
AMRI's Price-to-Operating-Cash-Flow is ranked lower than
85% of the 158 Companies
in the Global Biotechnology industry.

( Industry Median: 22.05 vs. AMRI: 77.11 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
AMRI' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 4.93  Med: 15.23 Max: 320.75
Current: 77.11
4.93
320.75
EV-to-EBITDA 120.76
AMRI's EV-to-EBITDA is ranked lower than
92% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 16.23 vs. AMRI: 120.76 )
Ranked among companies with meaningful EV-to-EBITDA only.
AMRI' s EV-to-EBITDA Range Over the Past 10 Years
Min: -39.8  Med: 9.9 Max: 147.1
Current: 120.76
-39.8
147.1
Days Inventory 97.25
AMRI's Days Inventory is ranked higher than
65% of the 314 Companies
in the Global Biotechnology industry.

( Industry Median: 129.42 vs. AMRI: 97.25 )
Ranked among companies with meaningful Days Inventory only.
AMRI' s Days Inventory Range Over the Past 10 Years
Min: 37.21  Med: 63.21 Max: 97.25
Current: 97.25
37.21
97.25
Days Sales Outstanding 81.20
AMRI's Days Sales Outstanding is ranked lower than
64% of the 405 Companies
in the Global Biotechnology industry.

( Industry Median: 62.87 vs. AMRI: 81.20 )
Ranked among companies with meaningful Days Sales Outstanding only.
AMRI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 43.89  Med: 61.34 Max: 100.17
Current: 81.2
43.89
100.17

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -6.70
AMRI's 3-Year Average Share Buyback Ratio is ranked higher than
64% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -10.60 vs. AMRI: -6.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AMRI' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -8.9  Med: -0.6 Max: 2.8
Current: -6.7
-8.9
2.8

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.73
AMRI's Price-to-Median-PS-Value is ranked higher than
69% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 0.99 vs. AMRI: 0.73 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
AMRI' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.3  Med: 1.37 Max: 19.94
Current: 0.73
0.3
19.94
Price-to-Peter-Lynch-Fair-Value 5.53
AMRI's Price-to-Peter-Lynch-Fair-Value is ranked lower than
99.99% of the 66 Companies
in the Global Biotechnology industry.

( Industry Median: 1.55 vs. AMRI: 5.53 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
AMRI' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0  Med: 1.48 Max: 6.29
Current: 5.53
0
6.29
Earnings Yield (Greenblatt) % -4.04
AMRI's Earnings Yield (Greenblatt) % is ranked higher than
56% of the 639 Companies
in the Global Biotechnology industry.

( Industry Median: -6.50 vs. AMRI: -4.04 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
AMRI' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -4.09  Med: 3.9 Max: 16.5
Current: -4.04
-4.09
16.5
Forward Rate of Return (Yacktman) % 17.55
AMRI's Forward Rate of Return (Yacktman) % is ranked higher than
55% of the 119 Companies
in the Global Biotechnology industry.

( Industry Median: 15.08 vs. AMRI: 17.55 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
AMRI' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -17.3  Med: 0.5 Max: 20.9
Current: 17.55
-17.3
20.9

More Statistics

Revenue (TTM) (Mil) $570.4
EPS (TTM) $ -1.84
Beta1.36
Short Percentage of Float22.65%
52-Week Range $12.45 - 19.35
Shares Outstanding (Mil)42.89

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 724 782
EPS ($) 1.11 1.33
EPS without NRI ($) 1.11 1.33
EPS Growth Rate
(Future 3Y To 5Y Estimate)
15.00%
Dividends per Share ($)
» More Articles for AMRI

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: TSON, PRTS, FXCM, AMRI, MN Dec 05 2011 

More From Other Websites
Albany Molecular Research, Inc. :AMRI-US: Earnings Analysis: Q4, 2016 By the Numbers : February 22,... Feb 22 2017
Albany Molecular Research 4Q Net Misses Street Feb 22 2017
Albany Molecular Research, Inc. breached its 50 day moving average in a Bearish Manner : AMRI-US :... Feb 22 2017
ALBANY MOLECULAR RESEARCH INC Files SEC form 8-K, Results of Operations and Financial Condition,... Feb 21 2017
Edited Transcript of AMRI earnings conference call or presentation 21-Feb-17 1:30pm GMT Feb 21 2017
Albany Molecular Research posts 4Q loss Feb 21 2017
Albany Molecular Research posts 4Q loss Feb 21 2017
AMRI Announces Agreement with Accord Healthcare to Jointly Develop, Manufacture and Commercialize... Feb 21 2017
AMRI Announces Fourth Quarter and Full Year 2016 Results and Provides 2017 Outlook Feb 21 2017
Q4 2016 Albany Molecular Research Inc Earnings Release - Before Market Open Feb 21 2017
[2/15] Today's Top 10 Long/Short Estimize Signal Scores Feb 15 2017
AMRI Schedules Fourth Quarter and Full Year 2016 Earnings Release and Conference Call Feb 15 2017
[2/7] Today's Top 10 Long/Short Estimize Signal Scores Feb 07 2017
AMRI Announces Strategic Alliance to Advance Mass Spectrometry Capabilities for Drug Discovery Feb 07 2017
Albany Molecular Research, Inc. – Value Analysis (NASDAQ:AMRI) : January 20, 2017 Jan 20 2017
Albany Molecular Research, Inc. breached its 50 day moving average in a Bullish Manner : AMRI-US :... Jan 19 2017
ALBANY MOLECULAR RESEARCH INC Files SEC form 8-K, Other Events Dec 22 2016
AMRI CEO to Present at 35th Annual J.P. Morgan Healthcare Conference Dec 13 2016
Is Instructure Inc (INST) A Good Stock to Buy? Dec 12 2016
Is Albany Molecular Research, Inc. (AMRI) A Good Stock To Buy? Dec 05 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)